Treatment of adult systemic mastocytosis with interferon‐α: results of a multicentre phase II trial on 20 patients
The DOI matches its Crossref record.
Abstract
Summary. Systemic mastocytosis (SM) is characterized by proliferation of mast cells in various organs, which may release a wide variety of mediators, thereby explaining the broad clinical spectrum of disease manifestations. The potentially life‐threatening systemic symptoms and tumoral proliferation are poorly controlled despite the use of several cytotoxic chemotherapies and/or symptomatic treatments. Twenty consecutive adult SM patients with histologically confirmed bone marrow (BM) involvement received interferon‐α subcutaneously (1–5 million units/m 2/d, with progressive dose intensification over the first month of treatment) and were evaluated after 6 months of therapy. Seven of them had previously received symptomatic treatments, including steroids, which were ineffective. Among the 13 patients treated for at least 6 months, seven partial and six minor responses, mainly concerning vascular congestion and skin lesions, were obtained, while BM infiltration remained unchanged in 12 patients. The significant reduction of mast‐cell mediator levels after 6 months of treatment was not predictive of clinical remission. The rate of depression was unexpectedly high (seven patients; 35%). Two patients died soon after starting therapy (one myocardial infarction, one septic shock). Six months of interferon‐α may relieve vascular congestion in adults with SM, probably by inhibiting mast‐cell degranulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts
Valent, P., Akin, C., & Metcalfe, D. D. (2017) · Blood · doi:10.1182/blood-2016-09-731893 · Cited by 592
Anaphylaxis—a practice parameter update 2015
Lieberman, P., Nicklas, R. A., Randolph, C., Oppenheimer, J., Bernstein, D., Bernstein, J., Ellis, A., Golden, D. B. K., Greenberger, P., Kemp, S., et al. (2015) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2015.07.019 · Cited by 474
Gaziano, L., Giambartolomei, C., Pereira, A. C., Gaulton, A., Posner, D. C., Swanson, S. A., Ho, Y.-L., Iyengar, S. K., Kosik, N. M., Vujkovic, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01310-z · Cited by 235
Leukotriene-receptor inhibition for the treatment of systemic mastocytosis
Tolar, J., Tope, W. D., & Neglia, J. P. (2004) · New England Journal of Medicine · doi:10.1056/nejm200402123500723 · Cited by 70
Metadata
- Authors
- Casassus, P., Caillat‐Vigneron, N., Martin, A., Simon, J., Gallais, V., Beaudry, P., Eclache, V., Laroche, L., Lortholary, P., Raphaël, M., Guillevin, L., & Lortholary, O.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2002-12
- Volume
- 119
- Issue
- 4
- Pages
- 1090-1097
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2077810015
- Cited by
- 157
- References
- 0
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of adult systemic mastocytosis with interferon‐α: results of a multicentre phase II trial on 20 patients. https://app.cochat.ai/papers/10.1046/j.1365-2141.2002.03944.x
- The paper
- Casassus, P., Caillat‐Vigneron, N., Martin, A., Simon, J., Gallais, V., Beaudry, P., Eclache, V., Laroche, L., Lortholary, P., Raphaël, M., Guillevin, L., & Lortholary, O. (2002). Treatment of adult systemic mastocytosis with interferon‐α: results of a multicentre phase II trial on 20 patients. British Journal of Haematology. https://doi.org/10.1046/j.1365-2141.2002.03944.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.